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Effect of cold atmospheric plasma treatment
on the metabolites of human leukemia cells
Dehui Xu1*†, Ning Ning2†, Yujing Xu1, Bingchuan Wang1, Qingjie Cui2, Zhijie Liu1, Xiaohua Wang1, Dingxin Liu1,
Hailan Chen3 and Michael G. Kong1,3,4*

Abstract
Background: Acute myeloid leukemia (AML) is a typically fatal malignancy and new drug and treatment need to
be developed for a better survival outcome. Cold atmospheric plasma (CAP) is a novel technology, which has been
widely applied in biomedicine, especially in various of cancer treatment. However, the changes in cell metabolism
after CAP treatment of leukemia cells have been rarely studied.
Methods: In this study, we investigated the metabolite profiling of plasma treatment on leukemia cells based on Gas
Chromatography Tandem Time-of-Flight Mass Spectrometry (GC-TOFMS). Simultaneously, we conducted a series of
bioinformatics analysis of metabolites and metabolic pathways with significant differences after basic data analysis.
Results: 800 signals were detected by GC–TOF mass-spectrometry and then evaluated using PCA and OPLS-DA. All
the differential metabolites were listed and the related metabolic pathways were analyzed by KEGG pathway. The
results showed that alanine, aspartate and glutamate metabolism had a significant change after plasma treatment.
Meanwhile, d-glutamine and d-glutamate metabolism were significantly changed by CAP. Glutaminase activity was
decreased after plasma treatment, which might lead to glutamine accumulation and leukemia cells death.
Conclusions: We found the above two metabolic pathways vulnerable to plasma treatment, which might result in
leukemia cells death and might be the cornerstone of further exploration of plasma treatment targets.
Keywords: Cold atmospheric plasma, Acute myeloid leukemia, Metabolite profiling, Alanine, aspartate and
glutamate metabolism, d-Glutamine and d-glutamate metabolism
Background
Acute myeloid leukemia (AML) is a myeloid cancer,
which is characterized by the rapid growth in the bone
marrow and blood [1]. AML is mainly treated with longterm chemotherapy and radiation therapy for the purpose of induction of remission, or treated with stem cell
transplantation [1, 2]. There is no doubt that these therapies bring about unavoidable harm to human normal
cells. Therefore, it’s necessary to develop a new technology for the treatment of acute myeloid leukemia.
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mkong@odu.edu
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Cold atmospheric plasma (CAP) is a new technology that has attracted much attention in recent years
especially in biomedical applications, such as bacterial
disinfection, application of skin diseases, dentistry, cell
transfection, wound healing and cancer treatment [3–8].
It is an ionized gas generated by electrical discharges in
the atmospheric pressure at room temperature [9]. It has
reported that plasma can effectively induce cell death in
various types of cancer cells, including colon cancer, melanoma, cervical cancer, glioma, multiple myeloma and so
on [10–17]. However, the effect of plasma treatment on
the metabolites of tumor cell has been rarely reported.
Cell metabolism, a general term for a series of ordered
chemical reactions, is one of the most important physiological mechanism to maintain the normal growth and
reproduction of organisms [18]. Cancer cells are able to
achieve rapid and explosive proliferation due to metabolic
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Fig. 1 a Schematic diagram; b physical map and discharge photograph of the surface plasma; c discharge parameters; d V–Q Lissajous figure of the
discharge powers; e emission spectra of the Surface plasma

reprogramming. Metabolic reprogramming is an oncogenic signaling, which facilitates assimilation of carbons
into macromolecules such as lipids, proteins and nucleic
acids to generate a large number of intermediate metabolites required for the growth and proliferation of cancer
cells [19–22]. Therefore, it’s of great necessity to understand the effects of gas plasma on tumor cell metabolism,
so as to treat cancer more precisely by plasma treatment.
Based on the above notion, we performed a metabolomic
analysis, which showed that the metabolites of leukemia
cells have changed a lot after plasma treatment. Importantly, we found that alanine, aspartate and glutamate
metabolism had a significant change, suggesting that alanine, aspartate and glutamate metabolism may exist critical targets for plasma treatment.

voltage and current respectively. Surface plasma was
maintained at an electrical power of 0.06 W/cm2. The
physical map of the surface discharge device and the
plasma interface were shown in the Fig. 1b.

Methods

The MOLM13 leukemia cell line was used in this study.
MOLM13 cells were cultured in Roswell Park Memorial
Institute (RPMI) 1640 medium coupled with 10% fetal
calf serum, 100 U/mL penicillin, and 50 µg/mL streptomycin (Gibco-Invitrogen, Carlsbad, CA, 15140-122).
Cell culture bottles were placed at 37 °C in an incubator
(Thermo Scientific, Waltham, MA, USA) containing 5%
CO2. The medium was refreshed 24 h before performing
experiments.

Surface plasma device

In this study, we used a surface plasma device. As shown
in Fig. 1a, the surface discharge structure of the plasma
consisted of a high-voltage (HV) electrode, a ground
electrode and a 1 mm thickness hexagonal polytetrafluroethylene (PTFE) sandwiched between the two electrodes.
The surface plasma was generated when a sinusoidal
high voltage at peak-to-peak value of 5 kV was applied.
We used a HV probe (Tektronix, P6015A) and a current probe (Tektronix, P6021) to measure the discharge

Optical emission spectroscopy

We used a UV/visible spectrometer (Maya pro 2000,
Ocean Optics, China) within a wavelength range of
200–800 nm to measure emission spectra of the surface
plasma. The optical probe was mounted directly away the
discharge area at 2 cm, which ensured a clear spectrum
when detecting the spectrum.
Cell culture condition
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We used a Cell-Titer-Glo® luminescent cell viability assay
kit (Promega, Madison, WI, USA) to measure cell viability, which was based on quantitation of the ATP (Adenosine triphosphate) to determine the number of viable cells
in culture medium. And we added 100 μL of samples and
100 μL of Cell-Titer-Glo® reagent to the opaque-walled
multiwell plate (96-well plates), and then the mixture was
incubated at room temperature for 10 min. We utilized
a microplate reader (Thermo Scientific Varioskan Flash,
Waltham, MA, USA) with the protocol of “luminometric” measurement to detect the luminescence.
Cell viability assessment

Solvents and reagents

L-2-chlorophenylalanine was purchased from Hengbai
Biotech Co Ltd (Shanghai, China). The methoxy amination hydrochloride (chromatographic grade), pyridine
and chloroform were all from Admas (Shanghai, China).
In addition, we bought BSTFA (including 1% TMCS, v/v)
from REGIS Technologies Inc (Morton Grove, IL, USA)
and methanol (HPLC grade) from ANPEL Laboratory
Technologies Inc (Shanghai, China). Saturated fatty acid
methyl lipids (C8, C9, C10, C12, C14, C16, C18, C20,
C22, C24) were purchased from Dr. Ehrenstorfer (Augsburg, Germany). Deionized water (Thermo; Waltham,
MA, USA) was used throughout the experiment. We
used 20 µΜ/L and 40 µM/L BPTES in DMSO for subsequent experimental verification.
Sample collection

We seeded 3 × 105 cells/well in 300 μL of the medium in
a 24-well plate. Wells were treated with gas plasma for
40 s as plasma treatment group, and the rest wells were
control group without any treatment, containing 5 replicates/samples in each group. After incubation for 24 h,
cells were collected and counted to ensure that the number of cells was about 1 × 107 cells/sample. Cells were
centrifuged at 4 °C for 5 min at the speed of 135g and
washed 3 times at 4 °C with PBS at the speed of 76g. Then
the cell mass in EP tube was placed in liquid nitrogen for
5 min rapidly and stored in the − 80 °C refrigerator until
it was analyzed.
Sample preparation

Before metabolite analysis, sample was that 0.6 ml extract
(V methanol: chloroform = 3:1) in 2 ml EP tube and 10
μL L-2-cholrophenylalanine (1 mg/mL stock in d
 H2O)
as internal standard were mixed. After vortex mixing
for 30 s, steel balls were added and ground at 45 Hz for
4 min, and then sonicated in ice water for 5 min. Next,
the above step was repeated 3 times. After centrifugation
at 15,871g, 4 °C for 15 min, the supernatant (0.5 mL) was
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transferred to a fresh 2 ml GC/MS glass vial. Then, the
extracted metabolites were dried in a vacuum concentrator without heating, and 30 μL of methoxylamine hydrochloride was added. After incubation in oven at 80 °C
for 30 min, 40 μL of BSTFA reagent (1% TMCS, v/v) was
thoroughly mixed with the sample aliquots and incubated at 70 °C for 1.5 h to obtain a derivative metabolite
for GC–MS analysis.
GC–TOF–MS analysis

We performed GC–TOF–MS analysis using an Agilent 7890 gas chromatograph system coupled with a
Pegasus HT Time-of-Flight Mass Spectrometer. The
system utilized a DB-5MS capillary column coated with
5% diphenyl cross-linked with 95% dimethylpolysiloxane (30 m × 250 μm inner diameter, 0.25 μm film thickness; J&W Scientific, Folsom, CA, USA). 1 μL aliquot of
the analyte was injected in splitless mode. Helium was
used as the carrier gas, the front inlet purge flow was
3 mL min−1, and the gas flow rate through the column
was 1 mL min−1. The initial temperature was kept at
50 °C for 1 min, then raised to 310 °C at a rate of 10 °C
m
 in−1, then kept for 8 min at 310 °C. The injection, transfer line, and ion source temperatures were 280, 280, and
250 °C, respectively. The energy was − 70 eV in electron
impact mode. The mass spectrometry data were acquired
in full-scan mode with the m/z range of 50–500 at a rate
of 20 spectra per second after a solvent delay of 6.27 min.
Data preprocessing and annotation

We used Chroma TOF 4.3X software of LECO Corporation and LECO-Fiehn Rtx5 database for exacting raw
peaks, filtering the data baselines and calibration of the
baseline, peak alignment, deconvolution analysis, peak
identification and integration of the peak area [23]. Both
of mass spectrum match and retention index match were
considered in metabolites identification.
Spectrophotometric detetion of GLS activity

We used a glutaminase (GLS) activity assay kit (Comin,
Suzhou, China) to measure GLS activity. The principle
was to measure the rate of ammonia production from
glutamine catalyzed by GLS to calculate the enzymatic
activity. We first collected leukemia cells into a centrifuge
tube (1 million cells), washed them 2–3 times with PBS,
centrifuged and discard the supernatant, and then added
400 µL extract, ultrasonically disrupted cells (sonicate
for 7–8 s, interval for 10–15 s, repeat 10 times, ice bath)
with power 200 W. After the above steps were completed,
we centrifuged the disrupted cells for 10 min at 4 °C to
take the supernatant. The supernatant and the reagent 1,
2 were mixed in 37 °C water bath for 1 h. Last, we used
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Fig. 2 Cell viability of normal bone marrow stromal cells and
MOLM-13 cells by plasma treatment

a spectrophotometer to read the absorbance of ammonia
at 420 nm.

Results
Plasma discharging parameter and characters

A sinusoidal power supply at f = 10 kHz and Vpp = 5 kV
was used to generate a surface plasma in ambient air.
Figure 1c showed the applied AC voltage curve and the
corresponding current curve when the surface plasma
discharging. A V–Q Lissajous figure of the discharge
powers was shown in Fig. 1d. The discharging characteristic of the surface plasma was depicted by an emission
spectra, as shown in Fig. 1e. There were several spectral
lines in the surface plasma (e.g. OH (A) 310 nm, N2 (C)
340 nm, N
 2+ (B) 390 nm).
Metabolic profiles of plasma‑treated cells by GC–TOF

We totally investigated 10 samples of MOLM13 leukemia cell line, of which five samples as the experimental
group were treated with plasma for 40 s and the other
five samples were not treated as experimental controls.
Figure 2 showed that cell viability of MOLM13 cell line
was decreased significantly with increasing plasma treatment time while cell viability of normal cell line derived
from normal bone marrow stromal cells was decreased
slightly. And the leukemia cell activity after the plasma
treatment for 40 s is about 70%, which is especially conducive to further metabolic analysis. Using Gas Chromatography Tandem Time-of-Flight Mass Spectrometry
(GC-TOFMS), we extracted 837 signals based on mass
spectral deconvolution software for peak detection. In
order to better analyze the data, we performed a series
of preprocessing on the raw data and finally 800 signals
were retained. Figure 3a showed the GC-TOFMS total

First, we made a principal component analysis (PCA)
after preprocessing the raw data. Because variables contain both differential variables related to categorical variables and large quantities of them irrelevant to each other,
the result of metabolic differences was not very significant, which was basically in the 95% confidence interval
(Hotelling’s T-squared ellipse). Therefore, this data was
be further analyzed using orthogonal least squares discriminant analysis (orthogonal projection to latent structure
discriminant analysis, OPLS-DA). Different from PCA,
OPLS-DA was a supervised statistical method for discriminant analysis. This method used OPLS-DA to establish
a relationship model between metabolite expression levels and sample categories to achieve prediction of sample categories. We filtered out the orthogonal variables
that were independent of the classified variables in the
metabolites and analyzed the differences between non
orthogonal and orthogonal variables in order to obtain
more reliable metabolites. The parameters of the OPLSDA model were shown in the statistical model parameter
Table 1. R2X and R
 2Y represented the interpretation rates
of the model for the matrix X and Y respectively, and Q
 2
denoted the prediction ability of the model. Theoretically,
the closer the value of R
 2 and Q2 is to 1, the better the
model is Table 1 showed that our OPLS-DA model could
be used for further verification.
As Fig. 3b shows, the X-axis denoted the predicted
principal component score of the first principal component, while the Y-axis showed the orthogonal principal
component score. The different scatter shape and color
represented different experimental groups respectively.
The results of the OPLS-DA score plot showed that the
two groups of samples were very distinct, and the samples were all at the 95% confidence interval. The OPLSDA permutation test was to avoid overfitting of the test
model and to ensure statistical significance of the evaluation model. The result of the permutation test of the
OPLS-DA model between plasma treatment group and
control group was shown in the Fig. 3c. The X-axis and
Y-axis represented the degree of substitution retention of
the permutation test and the value of R2Y or Q respectively. Green circles and blue square points denoted R2Y
value and Q value, which were obtained by the permutation test respectively. The two dotted lines indicated the
R2Y’s and Q’s regression lines. The result showed that the
original model had good robustness and there was no
overfitting phenomenon.
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Fig. 3 a GC-TOFMS total ion chromatogram; b score scatter plot of OPLS-DA model; c permutation test of OPLS-DA model

Table 1 Statistical model parameters table of OPLS-DA model
Model

Type

A

N

R2X (cum)

R2Y (cum)

Q2 (cum)

Model 1

OPLS-DA

1+1+0

10

0.426

0.999

0.875

Screening of differential metabolites

Based on the inherent characteristics of GC-TOFMS
metabolomic data, we used multivariate statistical analysis methods to analyze the data and screened out differential metabolites (Additional file 2) between plasma
treatment group and control group. P value of student’s
t-test is less than 0.05 and the first principal component’s
Variable Importance in the Projection (VIP) is greater
than 1. Volcano plot was a kind of image used to show the
difference data between groups, where the X-axis represented the fold change of the plasma treatment group
compared to the control group (base 2 logarithm) and
the Y-axis represented the student’s t-test P-value (base
10 logarithm). We visualized the above results of screening differential metabolites in the form of volcano plot
(Fig. 4). The result showed the significantly up-regulated
metabolites (red), down-regulated metabolites (blue),
and non-significant differential metabolites (gray). The
scatter size represented the VIP value of the OPLS-DA

model. The larger scatter was on behalf of the bigger VIP
value.
Cluster analysis

Heatmap uses color changes to reflect data information
in a two-dimensional matrix or table. It can visually represent the size of data value with defined depths of color.
The hierarchical clustering analysis can clear classify the
metabolites with the same and different characteristics
between the sample groups. The clustered data are represented on the heatmap, and the high abundance and low
abundance species can be clustered. The similarity and
diversity of the community composition at different levels can be reflected by the color gradient and similarity.
After hierarchical clustering analysis of the differential
metabolites between the surface plasma treatment group
and the control group, we visualized the obtained results
in a heatmap (Fig. 5). Clustering of samples using the
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significantly regulated metabolites resulted in a nearly
perfect separation of the plasma treatment group and
the control group. It indicated that there were significant
differences in the expression of metabolites between the
two groups.
All the pathways relevant to differential metabolites
by KEGG analysis

All the metabolites do not work alone and they are
involved with one or more metabolic pathways together
with other metabolites. Deregulation of differential
metabolites is also the result of mutual influence, which
even changes the expression of their own metabolic
pathways.
KEGG (Kyoto Encyclopedia of Genes and Genomes) is
a huge database used to systematically analyze gene functions, which can link genomic information to metabolites
functional information [24]. The PATHWAY database
utilizes a few direct homologous tables to obtain information about conserved subpathways that is usually
encoded by positionally coupled genes on the chromosome, which is particular useful for further understanding the metabolic changes of the pathway [24]. We
mapped all 800 metabolites to Homo sapiens in the
KEGG pathway database. And we also listed all the pathways for mapping differential metabolites, as shown in

Additional file 3. Next, we marked the differential metabolites on the KEGG pathway map. As shown in Fig. 6,
bright red dots represented up-regulation, while bright
blue dots represented down-regulation.
Metabolic pathway analysis related with differential
metabolites

To know whether these pathways were significantly
affected after plasma treatment, KEGG analysis was not
enough, therefore we further analyzed metabolic pathways for differential metabolites. By comprehensive
analysis of pathways where differential metabolites were
located (including enrichment analysis and topological
analysis), we further screened pathways and found the
key pathways with the highest correlation with differential metabolites. Metabolic pathway analysis results were
shown in Additional file 4.
The results of the metabolic pathway analysis were
shown as bubble diagram (Fig. 7). One metabolic pathway was represented by one bubble in the diagram. The
location of the X-axis of a bubble and the size of the bubble indicated impact value of a metabolic pathway, which
was from the topological analysis of metabolic pathway.
The location of the Y-axis of a bubble and the color of the
bubble indicated the P value of the enrichment analysis. Pathways with significant metabolic differences was
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screened by considering impact value of the topological
analysis and P value of the enrichment analysis. From the
bubble diagram, we could find out that alanine, aspartate
and glutamate metabolism pathway was the most significant changes after gas plasma treatment in MOLM13
cells. Furthermore, it was worth noting that d-glutamine
and d-glutamate metabolism were also significantly
changed in leukemia cells.
Inhibition of GLS after plasma treatment leading
to disruption of glutamine metabolism

We found that glutamine in alanine, aspartate and glutamate metabolism pathway and in d-glutamine and
d-glutamate metabolism pathway was up-regulated in
plasma treatment group (Fig. 5). Studies have shown that
glutamine metabolism plays an important role in biosynthesis, energy metabolism and cell homeostasis of
tumor cells and promotes tumor growth [25, 26]. Moreover glutaminase (GLS) is overexpressed in many tumor
cells and converts glutamine to glutamic acid, which is
then converted to ∝-KG and introduced into TCA cycle

[25]. We therefore hypothesized that glutaminase activity of plasma-treated leukemia cells was reduced and glutamine could not be normally metabolized and converted
to glutamic acid, which suppressed the proliferation of
leukemia cells and even leaded to leukemia cells apoptosis. This also explained why alanine, aspartate and glutamate metabolism are abnormal after plasma treatment.
To determine whether the differentially metabolic
pathway and the differential metabolite were responsible
for leukemia cells death, we analyzed glutaminase activity of leukemia cells before and after plasma treatment.
The result showed that glutaminase activity after plasma
treatment was reduced (Fig. 8a). Subsequently, we inhibited glutaminase activity with 20 µM/L and 40 µM/L
BPTES (bis-2-(5-Phenylacetmido-1,2,4-Thiadiazol-2-yl)
Ethyl Sulfide, GLS inhibitor) for 24 h, 48 h and 72 h. We
found that when glutaminase was inhibited (Fig. 8b), leukemia cells activity was decreased (Fig. 8c). Interestingly,
when we added glutamate to the experimental group
containing 20 µM/L BPTES for 48 h, relative cell activity
had a certain increase (Fig. 8d).
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Discussion
As a new developed technology, atmospheric-pressurecold plasma has aroused widespread concern in biomedical applications. It has reported that atmospheric cold
plasma can selectively induce various tumor cells death
[27, 28]. And a large number of metabolites have been
shown to contribute to distinguish tumors from healthy
tissue [29]. Therefore, it’s a new perspective to explore
changes in metabolites and metabolic pathways of tumor
cells before and after plasma treatment. This metabolic
study might be useful to identify metabolic pathways that
could be targeted for plasma treatment. In this way, the
bioenergetic state of the tumor can be destroyed more
specifically. In our study, we investigated the changes in
cell metabolism after CAP treatment of leukemia cells
by GC–TOF–MS analysis. From results, we found that
significant differences in metabolites between plasma
treatment group and control group. By multivariate
analysis, we screened for differential metabolites that

were significantly up-regulated or down-regulated. The
changes in the level of these differential metabolites were
not independent. On the contrary, they had mutual promotion or antagonism among them, which might affect
the level of certain metabolic pathways and further affect
the viability and metabolic level of cells. Therefore, it’s
important to analyze the metabolic pathways that have
the highest correlation with differential metabolites.
It has reported that several drugs such as A1CAR and
A-76969662 were able to upregulate AMPK signaling
directly or indirectly by activating the AMPK protein
complex so as to inhibit leukemia cells growth and even
induce apoptosis [30–32]. However, by KEGG analysis
of the metabolic pathways, we found that alanine, aspartate and glutamate metabolism had significant change
while AMPK signaling pathway had no change after
plasma treatment in leukemia MOLM13 cells. We next
focused on glutamine, the differential metabolite in alanine, aspartate and glutamate metabolism pathway and
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Fig. 8 Relative glutaminase activity of a leukemia cells after plasma treatment and b leukemia cells with 20 µM/L and 40 µM/L BPTES; Relative
cell viability of c leukemia cells with 20 µM/L and 40 µM/L BPTES and d leukemia cells with 20 µM/L BPTES vs. 20 µM/L BPTES adding glutamate.
*P < 0.05

in d-glutamine and d-glutamate metabolism pathway,
because many studies have showed that glutamine plays
an important role in signal transduction and proliferation
of tumor cells [26, 33]. The first step of glutamine catabolism occurs through the activation of glutaminase (GLS),
which catalyzes the conversion of glutamine to glutamic
acid. Inhibition of glutaminase can inhibit leukemia
cell growth and even induce apoptosis [34]. In cluster
analysis, we found that glutamine was upregulated after
plasma treatment. In order to determine its reason, we
investigated that GLS activity in leukemia cells after
plasma treatment, and the result showed that GLS activity was decreased. We also inhibited GLS activity of leukemia cells by BPTES and found that inhibiton of GLS
activity reduced cell viability. However, when added glutamate to leukemia cells inhibited GLS activity, we found
increased relative cell activity. The above results showed
that CAP treatment could inhibit the GLS activity of

leukemia cells so that glutamine was not able to be normally metabolized to produce glutamic acid and thus
accumulated, which might lead to leukemia cells death
due to the lack of required nutrients. Our current work
initially screened metabolites and metabolic pathways
with significant differences of leukemia cell after CAP
treatment with reduction of viability. At the same time,
we used pathway inhibitors to manipulate the perturbed
key pathway and analyzed the causes and effects of this
pathway change. With more details about the changes of
metabolic pathways induced by CAP treatment, it will be
a breakthrough to improve the treatment effect by CAP
in tumor therapy of leukemia or even other tumors.
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Conclusions
In conclusion, we analyzed the differential metabolites
in leukemia cell between plasma treatment group and
control group by bioinformatics analysis. More importantly, we found a crucial differential metabolic pathway,
alanine, aspartate and glutamate metabolism pathway,
which was vulnerable to plasma treatment. Its changes
may lead to leukemia cells apoptosis. Metabolomic analysis is therefore a promising approach to investigate the
key targets of plasma-treated tumor. The present study
may be a meaningful finding for further screening the
optimum target of plasma treatment for tumors.
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